v3.26.1
Schedule of Allocation of Purchase Price (Details) - USD ($)
 12 Months Ended
Jun. 02, 2025
Oct. 11, 2024
Dec. 31, 2025
Dec. 31, 2024
Assets and liabilities acquired:        
Goodwill     $ 5,878,986 $ 5,878,986
Loss on disposition     $ (1,534,517)
Five Narrow Lane LP [Member]        
Business Combination [Line Items]        
Common Stock   $ 214,937    
NAYA Acquisition Pre-funded Warrants   300,978    
Series C-1 Preferred   17,691,000    
Series C-2 Preferred   7,457,000    
Convertible Debenture   3,934,146    
Business acquisition cost   29,598,061    
Assets and liabilities acquired:        
Cash   472,008    
Other current assets   40,747    
Goodwill   17,656,707    
AP & accrued liabilities   (3,109,039)    
Debt   (290,362)    
Total assets and liabilities acquired   29,598,061    
Five Narrow Lane LP [Member] | Trade Names [Member]        
Assets and liabilities acquired:        
In process R&D   257,000    
Five Narrow Lane LP [Member] | In Process Research and Development [Member]        
Assets and liabilities acquired:        
In process R&D   $ 14,571,000    
NAYA Therapeutics [Member]        
Business Combination [Line Items]        
Series C-1 Preferred $ 2,466,810      
Business acquisition cost 11,149,596      
Assets and liabilities acquired:        
Cash 6,569      
Other current assets 16,700      
Goodwill 3,011,638      
AP & accrued liabilities (4,804,016)      
Debt (374,778)      
Loss on disposition 1,534,517      
NTI Note Receivable 4,803,175      
NTI Series A Preferred 3,879,611      
Net assets 12,684,113      
NAYA Therapeutics [Member] | Trade Names [Member]        
Assets and liabilities acquired:        
In process R&D 257,000      
NAYA Therapeutics [Member] | In Process Research and Development [Member]        
Assets and liabilities acquired:        
In process R&D $ 14,571,000